BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16796172)

  • 1. [Acetylcysteine in the treatment of severe COPD].
    Dekhuijzen PN
    Ned Tijdschr Geneeskd; 2006 Jun; 150(22):1222-6. PubMed ID: 16796172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of different treatment modalities on oxidative stress in COPD.
    Kuleci S; Hanta I; Kocabas A; Canacankatan N
    Adv Ther; 2008 Jul; 25(7):710-7. PubMed ID: 18592146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
    van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
    J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acetylcysteine in chronic obstructive pulmonary disease. Secretolytic, antioxidant or placebo?].
    Randerath W; Galetke W
    Med Monatsschr Pharm; 2003 Nov; 26(11):375-8. PubMed ID: 14652922
    [No Abstract]   [Full Text] [Related]  

  • 5. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease.
    Kasielski M; Nowak D
    Respir Med; 2001 Jun; 95(6):448-56. PubMed ID: 11421501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medical maintenance treatment of chronic obstructive pulmonary disease (COPD)].
    Kerstjens HA; Postma DS
    Ned Tijdschr Geneeskd; 2002 Aug; 146(35):1631-5. PubMed ID: 12233157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role for N-acetylcysteine in the management of COPD.
    Dekhuijzen PN; van Beurden WJ
    Int J Chron Obstruct Pulmon Dis; 2006; 1(2):99-106. PubMed ID: 18046886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease.
    Dekhuijzen PN
    Eur Respir J; 2004 Apr; 23(4):629-36. PubMed ID: 15083766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial.
    Decramer M; Rutten-van Mölken M; Dekhuijzen PN; Troosters T; van Herwaarden C; Pellegrino R; van Schayck CP; Olivieri D; Del Donno M; De Backer W; Lankhorst I; Ardia A
    Lancet; 2005 Apr 30-May 6; 365(9470):1552-60. PubMed ID: 15866309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxidation pathway and exacerbations in COPD: the role of NAC.
    Matera MG; Calzetta L; Cazzola M
    Expert Rev Respir Med; 2016; 10(1):89-97. PubMed ID: 26567752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease.
    Sutherland ER; Crapo JD; Bowler RP
    COPD; 2006 Dec; 3(4):195-202. PubMed ID: 17361500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
    Tse HN; Tseng CZ
    Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of circumstances of the development of chronic bronchitis in patients treated at Bydgoszcz Lung Disease Clinic in 1993-1996].
    Słowik-Gabryelska A
    Pol Merkur Lekarski; 1998 Dec; 5(30):321-4. PubMed ID: 10101513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis.
    Baker WL; Baker EL; Coleman CI
    Pharmacotherapy; 2009 Aug; 29(8):891-905. PubMed ID: 19637942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis.
    Sobieraj DM; White CM; Coleman CI
    Clin Ther; 2008 Aug; 30(8):1416-25. PubMed ID: 18803985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N-Acetylcysteine mucolysis in the management of chronic obstructive pulmonary disease.
    Sadowska AM
    Ther Adv Respir Dis; 2012 Jun; 6(3):127-35. PubMed ID: 22361928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erdosteine enhances airway response to salbutamol in patients with mild-to-moderate COPD.
    Dal Negro R; Visconti M; Trevisan F; Bertacco S; Micheletto C; Tognella S
    Ther Adv Respir Dis; 2008 Oct; 2(5):271-7. PubMed ID: 19124377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant effect of zinc picolinate in patients with chronic obstructive pulmonary disease.
    Kirkil G; Hamdi Muz M; Seçkin D; Sahin K; Küçük O
    Respir Med; 2008 Jun; 102(6):840-4. PubMed ID: 18295467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The 2007 GOLD Guidelines: a comprehensive care framework.
    Gold PM
    Respir Care; 2009 Aug; 54(8):1040-9. PubMed ID: 19650945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of N-acetylcysteine on exacerbations of chronic obstructive pulmonary disease: A meta-analysis and systematic review.
    Fowdar K; Chen H; He Z; Zhang J; Zhong X; Zhang J; Li M; Bai J
    Heart Lung; 2017; 46(2):120-128. PubMed ID: 28109565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.